Hypoglossal Nerve Stimulation (HGNS)
Treatment for Sleep Apnea
Typical Dosage: Device programmed settings
Effectiveness
80%
Safety Score
65%
Clinical Trials
14
Participants
5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
Device programmed settings
Time to Effect
2-3 months
Treatment Duration
Lifetime (with battery replacements)
Evidence Quality
MODERATENumber Needed to Treat (NNT)
2(Treat 2 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
25(Treat 25 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$0
Monitoring:$300
Side Effect Mgmt:$100
Total Annual:$4,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$75,000/QALY
QALYs Gained
1
Outcome-Based Costs
Cost per Responder
$6,923
Cost per Remission
$10,000
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
8 active trials recruiting for Hypoglossal Nerve Stimulation (HGNS) in Sleep Apnea
Metabolic Endpoints for Obstructive Sleep Apnea Following Twelfth Cranial Nerve Stimulation
NCT06317701RECRUITING
30 participants
OBSERVATIONAL
Chicago, United States
Started: Apr 4, 2024
Cardiometabolic Risk Effects of Short-term Cessation of Neurostimulation Therapy
NCT06720545RECRUITINGNA
60 participants
INTERVENTIONAL
New York, United States
Started: Jan 5, 2025
Hypoglossal Nerve Stimulation for the Treatment of Adult Obstructive Sleep Apnea
NCT07049744RECRUITINGNA
30 participants
INTERVENTIONAL
Canberra, Australia +4 more
Started: Jun 24, 2025
Obstructive Sleep Apnea Non-PAP Outcomes and Viable Alternatives
NCT07074288RECRUITINGNA
60 participants
INTERVENTIONAL
St Louis, United States
Started: Jun 30, 2025
Disrupted Sleep and Concurrent Ectopy or Atrial Fibrillation
NCT07220525RECRUITINGNA
100 participants
INTERVENTIONAL
San Francisco, United States
Started: Dec 15, 2025
Reducing Obstructive Sleep Apnea After Hypoglossal Nerve Stimulation Through Mandibular Advancement
NCT07132307RECRUITINGNA
30 participants
INTERVENTIONAL
St Louis, United States
Started: Jul 29, 2025
An Extension Study to Assess the Long-term Safety of the Genio® System
NCT05939141NOT YET RECRUITING
39 participants
OBSERVATIONAL
Sydney, Australia +6 more
Started: Nov 1, 2025
Safety and Effectiveness of the Genio® bilAteral Stimulation for Treatment of Complete Concentric CollapsE and OSA.
NCT05592002ACTIVE NOT RECRUITINGNA
124 participants
INTERVENTIONAL
Colorado Springs, United States +15 more
Started: Dec 28, 2022
Completed Clinical Trials
4 completed trials for Hypoglossal Nerve Stimulation (HGNS) in Sleep Apnea
Hypoglossal Nerve Stimulation on Cardiovascular Outcomes
NCT03359096COMPLETEDNA
63 participants
INTERVENTIONAL
Philadelphia, United States
Started: Dec 13, 2017
Mechanisms of Upper Airway Obstruction
NCT04322097COMPLETEDNA
133 participants
INTERVENTIONAL
Philadelphia, United States
Started: Jun 3, 2020
US Clinical Study of the Apnex Medical Hypoglossal Nerve Stimulation (HGNS) System to Treat Obstructive Sleep Apnea
NCT01211444COMPLETEDPHASE2, PHASE3
20 participants
INTERVENTIONAL
San Francisco, United States +3 more
Started: Jul 1, 2010
Australian Clinical Study of the Apnex Medical HGNS System to Treat Obstructive Sleep Apnea
NCT01186926COMPLETEDPHASE2, PHASE3
40 participants
INTERVENTIONAL
Started: Mar 1, 2009